Dermira Inc (DERM) : Simplex Trading reduced its stake in Dermira Inc by 31.47% during the most recent quarter end. The investment management company now holds a total of 7,733 shares of Dermira Inc which is valued at $268,799 after selling 3,551 shares in Dermira Inc , the firm said in a disclosure report filed with the SEC on Oct 7, 2016.Dermira Inc makes up approximately 0.04% of Simplex Trading’s portfolio.
Other Hedge Funds, Including , Bnp Paribas Arbitrage Sa boosted its stake in DERM in the latest quarter, The investment management firm added 888 additional shares and now holds a total of 1,706 shares of Dermira Inc which is valued at $59,778.
Dermira Inc closed down -0.17 points or -0.49% at $34.76 with 1,29,375 shares getting traded on Friday. Post opening the session at $34.92, the shares hit an intraday low of $34.5748 and an intraday high of $35.6199 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
Dermira Inc. is a specialty biopharmaceutical company focused on bringing medical dermatology products to dermatologists and their patients. The Company’s portfolio of five product candidates includes three late-stage product candidates. The late-stage product candidates are Cimzia (certolizumab pegol) which the Company is developing in collaboration with UCB Pharma S.A. (UCB) DRM04 and DRM01. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor or TNF inhibitor that is approved and marketed by UCB for the treatment of numerous inflammatory diseases spanning multiple medical specialties. DRM04 is a topical small-molecule anticholinergic product the Company is developing for the treatment of hyperhidrosis or excessive sweating. DRM01 is a topical small-molecule sebum inhibitor the Company is developing for the treatment of acne.